Abstracts Archive - Page 419 of 2425 - ACR Meeting Abstracts

Abstract Number: 2220 • ACR Convergence 2022
Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patients Receiving JAK Inhibitors in South Korea: A Nationwide Population-based Study
YoungEun Kim¹, Ye-Jee Kim², Seonok Kim², Soo Min Ahn¹, Ji Seon Oh³, Yong Gil Kim¹, Chang Keun Lee¹, Bin Yoo¹, Sang Hyoung Park⁴ and Seokchan Hong¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ³Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea, ⁴Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors are known to increase the risk of herpes zoster (HZ) reactivation; however, studies on the risk of HZ recurrence when…
Abstract Number: 2224 • ACR Convergence 2022
Genes Causative of Primary Immunodeficiency Are Risk Factors for and Over-expressed in Systemic Lupus Erythematosus
Haley Davis¹, Adam Labonte¹, Katherine Owen², Erika Hubbard¹, Jessica Kain¹, Brian Kegerreis¹, Prathyusha Bachali³, Amrie Grammer⁴ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²RILITE, Crozet, VA, ³AMPEL BioSolutions, Redmond, WA, ⁴AMPEL LLC, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is a polygenic autoimmune disease whose specific causes are incompletely understood and for which there exists no single comprehensive diagnostic…
Abstract Number: 2219 • ACR Convergence 2022
Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
Beth Wallace¹, Yuqing Gao², H. Myra Kim³, Punyasha Roul⁴, Ted Mikuls⁵, Daniel Clauw⁶, Bryant England⁷, Joshua Baker⁸, Brian Sauer⁹, Grant Cannon¹⁰, Shirley Cohen-Mekelberg¹, Wyndy Wiitala², Jeremy Sussman¹, Rodney Hayward¹ and Akbar Waljee¹, ¹University of Michigan Department of Internal Medicine; Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³Center for Statistical Consultation and Research, University of Michigan; Center for Clinical Management Research, VA Ann Arbor Healthcare Center, Ann Arbor, MI, ⁴UNMC, Omaha, NE, ⁵Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Michigan Department of Anesthesia, Ann Arbor, MI, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ¹⁰Retired, Salt Lake City, UT
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) at some point to manage RA symptoms. Prior work suggests recent GC use is associated with major…
Abstract Number: 2208 • ACR Convergence 2022
Diagnostic Performance of Hip Ultrasound in Calcium Pyrophosphate Deposition Disease
Carina Soto-Fajardo¹, Fabian Carranza-Enriquez², Sinthia Solorzano Flores², Abish Angeles², Paola Flores², Raul Pichardo-Bahena², Luis Javier Jara Quezada², Angélica Peña Ayala², Victor-Manuel Ilizaliturri-Sanchez², Georgios Filippou³ and Carlos Pineda², ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ²Instituto Nacional de Rehabilitacion, Ciudad de México, Mexico, ³Rheumatology Department, Luigi Sacco University Hospital, Siena, Italy
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a chronic and potentially incapacitating disease. The reference standard for its diagnosis is the identification of calcium pyrophosphate…
Abstract Number: 2230 • ACR Convergence 2022
Ultra-Rare Genetic Variation in Relapsing Polychondritis: A Whole-Exome Sequencing Study
Yiming Luo¹, Marcela Ferrada¹, Keith Sikora², Daniel Kastner³, Zuoming Deng⁴, Mengqi Zhang⁵, Hugh Alessi¹, Virginia Kraus⁶, Andrew Allen⁶ and Peter Grayson⁷, ¹National Institutes of Health, Bethesda, MD, ²National Institutes of Health Clinical Center, Bethesda, MD, ³National Human Genome Research Institute, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Duke University, Durham, NC, ⁷National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare rheumatic disease of unknown etiology characterized by inflammations of cartilaginous structures and other tissues, particularly the ears, nose,…
Abstract Number: 2231 • ACR Convergence 2022
Earlier and More Aggressive Treatment of Major Organ Involvement with Biologics May Prevent Relapses or Further New Organ Involvement in Behçet’s Disease
Tugce Bozkurt¹, Murat Karabacak¹, Hakan Karatas¹, seda kutluğ ağaçkıran², Tulin Ergun³, Haner Direskeneli⁴ and Fatma Alibaz-Oner⁵, ¹Marmara University, Istanbul, Turkey, ²Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, ³Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, ⁴Marmara University, Rheumatology, Istanbul, Istanbul, Turkey, ⁵Marmara University, Rheumatology, Istanbul, Turkey
Background/Purpose: Behçet's disease (BD) is a chronic inflammatory disease affecting the eye, nervous system (CNS), vascular and gastrointestinal systems (GIS) as well as skin, mucosa,…
Abstract Number: 2236 • ACR Convergence 2022
Association of microRNA-30b Plasma Expression with Fibromyalgia Clinical Features and with Corneal Small Nerve Fiber Pathology
Laura Aline Martínez Martínez¹, Fausto Sánchez Muñoz¹, Manuel Ramírez Fernández², Yaneli Juárez Vicuña¹, Mario Peña-Peña¹, Carlos Alfonso Guzman Martin¹, Itzel Palafox Sosa¹ and Manuel Martínez-Lavín¹, ¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ²APEC Hospital de la ceguera, Ciudad de México, Mexico
Background/Purpose: There is a clear association between fibromyalgia and small fiber neuropathy. Dorsal root ganglia contain the small nerve fiber nuclei. Severe fibromyalgia is associated…
Abstract Number: 2233 • ACR Convergence 2022
Machine Learning Uncovers Novel mRNAs Expressed in Fibromyalgia
Lena Kolb¹, Mark Rudolph¹, Alan Kivitz², Scott Rey¹, Roberta Alexander¹, Anja Kammesheidt³ and Geoffrey Stephens¹, ¹Exagen, Inc., Vista, CA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³self, Laguna Beach, CA
Background/Purpose: Fibromyalgia is a debilitating pain condition that affects roughly 12 million people in the United States. Although preliminary diagnostic criteria have been established by…
Abstract Number: 2218 • ACR Convergence 2022
Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
Namrata Singh¹, Laura Gold², Katherine Wysham³, James Andrews², Pankti Reid⁴, Una Makris⁵, Bryant England⁶, Jiha Lee⁷, Michael George⁸, Joshua Baker⁹, Jeffrey Jarvik², Patrick Heagerty² and Siddharth Singh¹⁰, ¹University of Washington, Bellevue, WA, ²University of Washington, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Chicago Medical Center, Chicago, IL, ⁵UT Southwestern Medical Center and Dallas VA, Dallas, TX, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ¹⁰University of California San Diego, San Diego
Background/Purpose: Recently, it has been recognized that frailty and pre-frailty are common in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased…
Abstract Number: 2237 • ACR Convergence 2022
Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Idiopathic Inflammatory Myopathy: Results of the 24-Week Double-Blind and 28-Week Open-Label Periods
Rohit Aggarwal¹, Ingrid Lundberg², Yeong-Wook Song³, Aziz Shaibani⁴, Victoria Werth⁵ and Michael Maldonado⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ³Seoul National University, Seoul, Republic of Korea, ⁴Nerve and Muscle Center of Texas, Houston, TX, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: A 52-week (wk), randomized, placebo (PBO)-controlled phase 3 trial of subcutaneous (SC) abatacept (ABA) and standard of care (SOC) was performed in patients (pts)…
Abstract Number: 2207 • ACR Convergence 2022
Structural Ultrasound Features of Joints and Tendons of Healthy Children: Development of Normative Data
Ruth Wittoek¹, Céline Decock², Nele Dewaele², Lara Arnold³, Pieter baeyens⁴, Ignace Deschrijver⁴, Lisa Pardaens⁵, Ioannis Raftakis⁶, Thomas Renson⁷, Alexander D.J. Thooft⁸, Charline Rinkin⁹, Tine Vanhaverbeke⁵ and Caroline Verbist¹⁰, ¹Dept. of Rheumatology, Ghent University Hospital, Ghent University, Gent, Belgium, ²Ghent University, Faculty of Medicine, Ghent, Belgium, ³Dept. Of Rheumatology, Maastricht UMC+, Maastricht, Netherlands, ⁴Dept. of Radiology, Clinique de Flandre, Coudekerque-Branche, France, ⁵Ghent University, Faculty of Internal Medicine and Pediatrics, Gent, Belgium, ⁶Dept. of Rheumatology, CHU-Brugmann Hospital Brussels, Brussels, Belgium, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Ghent University, Faculty of Internal Medicine and Pediatrics, Ghent, Belgium, ⁹Dept. of Rheumatology, CHU Liège, Liège, Belgium, ¹⁰Dept. of Rheumatology, AZ Delta, Roeselare, Belgium, Roeselare, Belgium
Background/Purpose: Ultrasound is a highly valuable imaging modality to study joints in patients with rheumatic diseases. In children, the applicability is hampered because of lack…
Abstract Number: 2210 • ACR Convergence 2022
Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study
Athimalaipet Ramanan¹, Pierre Quartier Dit Maire², Nami Okamoto³, Gabriella Meszaros⁴, Joana Araujo⁴, Zhongkai Wang⁴, Ran Liao⁴, Brenda Crowe⁴, Xin Zhang⁴, Rodney Decker⁴, Stuart Keller⁴, Hermine Brunner⁵ and Nicola Ruperto⁶, ¹Bristol Royal Hospital for Children, Bristol, United Kingdom, ²Necker hospital, Paris Cedex 15, France, ³Osaka Medical College, Takatsuki-city, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ⁶IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Baricitinib is a JAK1/2 selective inhibitor approved for the treatment of rheumatoid arthritis. Juvenile idiopathic arthritis (JIA) is a group of diseases characterized by…
Abstract Number: 1823 • ACR Convergence 2022
Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
Tamer A Gheita¹, Ahmed M Elsaman², Aly Bakhiet³, Mohamed Bakrey Mahmoud⁴, Faten Ismail⁵, Hanan El Saadany⁶, Rawhya R ElShereef⁵, Eman F Mohamed⁷, Mervat I Abd Elazeem⁸, Ayman Eid⁸, Fatma Ali⁵, Mona Hamdy⁵, Reem El Mallah⁹, Reem HA Mohammed¹, Samar Tharwat¹⁰, Rania M Gamal¹¹, Samar Fawzy¹, Soha Senara¹², Hanan M Fathi¹², Adham Aboul Fotouh¹³ and Nevin Hammam¹⁴, ¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ²Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ³Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, ⁴Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, ⁵Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ⁶Rheumatology Department, Tanta University, Gharbia, Egypt, ⁷Internal Medicine Department, Rheumatology Unit, Faculty of Medicine (Girls), Al-Azhar University, Cairo, Egypt, ⁸Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ¹⁰Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt, ¹³Egyptian School for Musculoskeletal Ultrasonography (EgySMUS); Egyptian Society of Musculoskeletal and Neuromuscular Sonography (ESMNS), Cairo, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA
Background/Purpose: Gout comprises a heterogeneous group of disorders characterized by inflammatory arthritis associated with comorbidities leading to impaired quality of life, and an extensive burden…
Abstract Number: 2079 • ACR Convergence 2022
Survey to Prioritize and Generate Domains in Preparation to Update the OMERACT Core Domain Set for Systemic Lupus Erythematosus
Wils Nielsen¹, Vibeke Strand², Lee S Simon³, Julian Thumboo⁴, Marta Mosca⁵, Martin Aringer⁶, Sindu Johnson⁷, Aaron Drucker⁷, Eric Morand⁸, Ian N. Bruce⁹ and Zahi Touma¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²Stanford University School of Medicine, Stanford, CA, ³SDG LLC, West Newton, MA, ⁴Singapore General Hospital, Bukit Merah, Singapore, ⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁶University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ⁷University of Toronto, Toronto, ON, Canada, ⁸Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ⁹Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: The development of a Core Outcome domain Set (COS) can aid research communication and standardizing measurement tools of SLE. A COS captures SLE facets…
Abstract Number: 1822 • ACR Convergence 2022
A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia
Marc Gurwith¹, Deon Smith², Paul Bird³, Jessica Leung⁴, Mark Bloch⁵, Joshua Kim⁶, Rahul Mohan⁷, Anthony Houston⁸, Oscar Cumming⁹, Ann Madrid¹⁰, Ullrich Schwertschlag¹¹, Jerry Liu¹², Roy Wu¹³, Jason Xu¹⁴, Adam Jin¹⁴ and William Dongfang Shi¹⁵, ¹Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Los Altos Hills, CA, ²Emeritus Research, Melbourne, Australia, ³Emeritus Research Sydney, Sydney, Australia, ⁴Austin Health, Preston, Victoria, Australia, ⁵Holdsworth House Medical Practice, Darlinghurst, Australia, ⁶Paratus Clinical Pty Ltd., New South Wales, Australia, ⁷Paratus Clinical Pty Ltd, Western Sydney, Australia, ⁸Peninsula Private Hospital, Kippa-Ring, Australia, ⁹Novatrials, Kotara, Australia, ¹⁰Novotech Australia, Sydney, Australia, ¹¹Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Palo Alto, ¹²Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., San Diego, ¹³Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., San Francisco, ¹⁴Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Suzhou, China, ¹⁵Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Fremont
Background/Purpose: ABP-671, a novel selective and potent URAT1 inhibitor reduces reabsorption of uric acid (UA) at the renal proximal tubule, and significantly decreases serum uric…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].